Skip to main content
Journal cover image

Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction.

Publication ,  Journal Article
Lin, C-H; Chen, J-K; Ko, T-M; Wei, C-Y; Wu, J-Y; Chung, W-H; Chen, S-Y; Liao, Y-D; Hung, S-I; Chen, Y-T
Published in: J Allergy Clin Immunol
April 2015

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Allergy Clin Immunol

DOI

EISSN

1097-6825

Publication Date

April 2015

Volume

135

Issue

4

Start / End Page

1063 / 1065.e5

Location

United States

Related Subject Headings

  • T-Lymphocytes
  • T-Cell Antigen Receptor Specificity
  • Pharmacogenetics
  • Lymphocyte Activation
  • Humans
  • HLA-B Antigens
  • Drug-Related Side Effects and Adverse Reactions
  • Allopurinol
  • Allergy
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lin, C.-H., Chen, J.-K., Ko, T.-M., Wei, C.-Y., Wu, J.-Y., Chung, W.-H., … Chen, Y.-T. (2015). Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction. J Allergy Clin Immunol, 135(4), 1063-1065.e5. https://doi.org/10.1016/j.jaci.2014.09.041
Lin, Chia-Hsien, Jung-Kuei Chen, Tai-Ming Ko, Chun-Yu Wei, Jer-Yuarn Wu, Wen-Hung Chung, Shih-Yang Chen, You-Di Liao, Shuen-Iu Hung, and Yuan-Tsong Chen. “Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction.J Allergy Clin Immunol 135, no. 4 (April 2015): 1063-1065.e5. https://doi.org/10.1016/j.jaci.2014.09.041.
Lin C-H, Chen J-K, Ko T-M, Wei C-Y, Wu J-Y, Chung W-H, et al. Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction. J Allergy Clin Immunol. 2015 Apr;135(4):1063-1065.e5.
Lin, Chia-Hsien, et al. “Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction.J Allergy Clin Immunol, vol. 135, no. 4, Apr. 2015, pp. 1063-1065.e5. Pubmed, doi:10.1016/j.jaci.2014.09.041.
Lin C-H, Chen J-K, Ko T-M, Wei C-Y, Wu J-Y, Chung W-H, Chen S-Y, Liao Y-D, Hung S-I, Chen Y-T. Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction. J Allergy Clin Immunol. 2015 Apr;135(4):1063-1065.e5.
Journal cover image

Published In

J Allergy Clin Immunol

DOI

EISSN

1097-6825

Publication Date

April 2015

Volume

135

Issue

4

Start / End Page

1063 / 1065.e5

Location

United States

Related Subject Headings

  • T-Lymphocytes
  • T-Cell Antigen Receptor Specificity
  • Pharmacogenetics
  • Lymphocyte Activation
  • Humans
  • HLA-B Antigens
  • Drug-Related Side Effects and Adverse Reactions
  • Allopurinol
  • Allergy
  • 3204 Immunology